Alpha IVF Group Expansion: New Centers Planned Through 2027
Alpha IVF Group Bhd is strategically expanding its network of in vitro fertilisation (IVF) centers, with plans to open four additional facilities by the end of 2027. This expansion aims to capitalize on growing trends in delayed parenthood, medical tourism, and increasing global demand for IVF services. The company’s recent performance indicates a positive trajectory, with revenue growth and increasing patient volumes.
Recent Financial Performance
In the third quarter of financial year 2026 (3QFY26), Alpha IVF Group reported revenue of RM47.12 million, a 16.06% increase compared to RM40.60 million in the same period last year. Net profit for the quarter rose to RM12.4 million, or 0.26 sen per share, bringing the nine-month profit to RM39.7 million, or 0.82 sen. This growth is attributed to higher patient numbers, particularly from local and Chinese patients seeking treatment at Malaysian centers.
New Center Openings and Performance
Alpha IVF Group launched two new full-fledged IVF centers in December 2025, located in Kota Kinabalu (KK) and Manila, bringing the total number of centers to six. These centers collectively generated RM1.5 million in revenue during 3QFY26. While the Kota Kinabalu center initially operated at a loss due to guaranteed income payments to doctors, it achieved earnings before interest, taxes, depreciation, and amortisation (EBITDA) positivity in February. The Manila center was EBITDA positive in 3QFY26 despite the typically slower holiday season.
Future Expansion Plans
Beyond the recently opened centers, Alpha IVF Group is developing additional facilities in Johor, Malaysia, and Tuguegarao, Philippines, expected to be operational by the first half of 2027. The company is also actively pursuing expansion in Indonesia, with planned centers in Jakarta and Bali. The Jakarta facility is anticipated to begin operations in the first half of 2027, while the Bali center is slated for completion by the end of 2027.
Profitability and Outlook
Alpha Singapore is projected to return to profitability by June 2026. TA Research, a research house, maintains a “buy” call on the stock with an unchanged target price of 37 sen a share, based on a price-to-earnings multiple of 23 times 2027 earnings per share. The firm has not altered its earnings projections for FY26 to FY28.
Key Takeaways
- Alpha IVF Group is expanding its regional presence with four new IVF centers planned by the end of 2027.
- Recent financial results present strong revenue growth and increasing profitability.
- New centers in Kota Kinabalu and Manila are contributing to revenue, with expectations for further growth as they mature.
- Expansion into Indonesia is a key part of the company’s long-term strategy.